Highest-materiality recent filing
Eledon Q2 net loss $31.6M; cash $88.8M; Phase 3 kidney trial on track
Cash $88.8M at June 30, 2026 vs $133.3M at Dec 31, 2025; expected to fund ops into Q2 2027.
Eledon stockholders approve increase in authorized common shares from 300M to 450M
Elected three Class III directors: David-Alexandre C. Gros, M.D., Jan Hillson, M.D., James Robinson for terms ending 2029.
Eledon Q1 net loss $39M; cash $111.1M; 100% insulin independence in islet trial
Cash, equivalents and short-term investments $111.1M as of March 31, 2026, down from $133.3M at Dec 31, 2025; funding expected into Q2 2027.
Eledon FY2025 net loss $45.6M; tegoprubart data shows insulin independence in T1D islet transplant
Net loss for FY2025 was $45.6M ($0.52/share) vs $36.2M loss in FY2024; non-GAAP net loss (excl warrant gain) was $79.1M.
Eledon exchanges 4.2M shares for pre-funded warrant with Coastlands
Exchange of 4,203,764 common shares for pre-funded warrant at $0.001 exercise price.
Eledon reports Q3 net loss $17.5M; Phase 2 BESTOW positive; raises $57.5M
Net loss $17.5M ($0.21/shr) vs net income $77M (incl $96.4M warrant gain) in Q3 2024.
Eledon raises ~$46.5M in public offering of common stock and pre-funded warrants
Underwritten offering of 15.15M shares at $1.65/share and up to 15.15M pre-funded warrants at $1.649/warrant.
Primary efficacy endpoint (eGFR at 12 months) did not reach statistical significance: 69 vs 66 mL/min/1.73 m².
Eledon Pharmaceuticals Restates Prior Financials and Reports Q2 2025 Results
Restated financial statements for fiscal years 2023 and 2024 and Q1 2025 due to misclassification of Series X and X1 preferred stock; will reclassify as temporary equity.
On-treatment patients (n=12) showed mean eGFR ~68 mL/min/1.73m² at 12 months; ITT population (n=15) ~63 mL/min/1.73m².
Eledon shareholders approve increase in authorized common shares to 300M
Shareholders approved increase in authorized common stock from 200M to 300M shares (40.79M for, 0.49M against).
Eledon Q1 net loss $6.5M; cash $124.9M; on track for BESTOW topline in Q4
Net loss of $6.5M ($0.08/share) vs $23.6M loss in Q1 2024; adjusted net loss $16.6M vs $10.3M.
Eledon Pharmaceuticals amends 8-K to correct auditor dismissal period; Crowe served only FY 2024
Corrects prior 8-K that inadvertently referenced Crowe LLP for fiscal year 2023.
Eledon Pharmaceuticals dismisses Crowe LLP, appoints Deloitte as auditor
Audit Committee dismissed Crowe LLP as independent auditor effective April 1, 2025.
Eledon Q4 net loss $44.6M; cash runway extended; tegoprubart used in pig kidney transplant
Q4 2024 net loss $44.6M ($0.64/shr) vs $30.1M ($1.00/shr) in Q4 2023; includes non-cash warrant loss $20.9M.
Eledon amends CEO Performance Bonus; increases max payout to $15M at $1.5B market cap
CEO David-Alexandre Gros' employment agreement amended to modify Performance Bonus market value cap.
Eledon completes BESTOW enrollment early; reports $77M net income on non-cash gain
Phase 2 BESTOW trial for tegoprubart in kidney transplant hit target of 120 patients ~4 months ahead of schedule.
Eledon Pharmaceuticals prices $85M offering of common stock and pre-funded warrants at $3.65/share
Gross proceeds ~$85M; net proceeds ~$79.5M after underwriting discounts and expenses.
Eledon's tegoprubart enables insulin independence in first two islet transplant recipients with T1D
First two subjects achieved insulin independence post-transplant; third subject on trajectory with >60% insulin reduction at day 3.
Eledon Pharmaceuticals raises ~$4M via private placement of 1.727M shares
Sold 1,527,400 shares on Sept 30 and 200,000 shares on Oct 1, 2024.
Eledon Pharmaceuticals enters $75M at-the-market equity facility with Guggenheim Securities
ATM sales agreement with Guggenheim Securities for up to $75M in common stock sales.
Non-reliance on FY2023 and Q1 2024 financials due to warrant derivative accounting error; expects restatement and amendments.
Eledon Pharmaceuticals replaces auditor KMJ Corbin with Crowe LLP; no disagreements reported
Audit committee dismissed KMJ Corbin and appointed Crowe LLP on July 10, 2024, after KMJ partners joined Crowe.
Stockholders approved amendment to 2020 Long Term Incentive Plan, increasing share reserve by 3.5M to 17.96M shares and extending grant period to May 2034.
Eledon Pharmaceuticals completes $2.1M unregistered stock sale of 909,088 shares
Sold 909,088 shares of common stock in second closing under Securities Purchase Agreement dated April 28, 2023.
Eledon Q1 net loss $10.3M ($0.34/share); cash $42.9M; $50M private placement
Net loss of $10.3M ($0.34 diluted EPS) vs $10.8M loss ($0.75 EPS) in Q1 2023.
Eledon raises $50M in oversubscribed private placement; tegoprubart advances in transplant trials
Gross proceeds ~$50M from 13.1M shares at $2.37/sh and 7.99M pre-funded warrants at $0.001/sh.
Eledon posts Q4 net loss $9.6M, highlights Phase 2 BESTOW enrollment and xenotransplant use
Net loss of $9.6M ($0.32/shr) for Q4 2023; full year net loss $40.3M ($1.64/shr).
Eledon reports Q3 net loss $10.3M ($0.35/sh); cash $59.6M; advances tegoprubart trials
Net loss of $10.3M ($0.35 per share) vs $10.5M ($0.73) YoY; R&D spend $7.9M.
Eledon reports Phase 1b data: tegoprubart prevents rejection with eGFR >70 in kidney transplant
Data from 11 participants showed no graft loss or death; one mild T cell mediated rejection (Banff 1a) on day 99 treated successfully.
Eledon Pharmaceuticals appoints Dr. Allan Douglas Kirk to board of directors
Board expands from 8 to 9 directors; Dr. Kirk effective Oct 2, 2023.
Eledon Pharmaceuticals adopts updated director and officer indemnification agreement
Board approved new form of indemnification agreement for all directors and officers.
Eledon Pharmaceuticals appoints James Robinson to board effective Oct 1, 2023
Robinson will serve as chair of the Compensation Committee and member of Audit Committee.
Eledon reports Q2 net loss $9.6M; cash $71.4M; raises up to $185M
Net loss of $9.6M ($0.40 per share) in Q2 2023 vs $9.2M ($0.65 per share) in Q2 2022.
Eledon shareholders approve 9.6M share increase to 2020 incentive plan at annual meeting
Amended 2020 Long Term Incentive Plan: share reserve raised from 4.86M to 14.46M shares.
Eledon reports Q1 net loss $10.8M; clinical and financing updates on tegoprubart
Net loss of $10.8M ($0.75/share) vs $9.9M ($0.69) in Q1 2022; R&D expenses rose to $8.1M.
Upfront $35M private placement (15.2M shares + warrants at $2.31/share); potential $105M milestone tranches and $45M warrant exercise.
Q4 2022 net loss $58.4M ($4.09/share) vs $8.8M ($0.59) in Q4 2021; full-year net loss $88.0M ($6.16) vs $34.5M ($2.33).
Eledon prioritizes kidney transplant program for tegoprubart; Phase 1b data expected Q1 2023
Ph 1b kidney transplant trial enrollment ongoing; initial 3- and 6-month data at World Congress of Nephrology March 2023.
Eledon reports Q3 net loss $10.5M; advances tegoprubart with FDA IND clearances
Net loss of $10.5M ($0.73/share) vs $9.8M ($0.66/share) in Q3 2021.
Eledon Q2 net loss $9.2M; advances tegoprubart trials across kidney, IgAN, ALS
Net loss of $9.2M ($0.65 per share) vs $7.4M loss in Q2 2021.
Eledon Pharmaceuticals annual meeting elects directors and ratifies auditor
Stockholders elected Keith A. Katkin (7,330,714 for, 765,231 withhold) and John S. McBride (7,287,222 for, 808,723 withhold) as Class II directors for term ending 2025.
Eledon reports positive Phase 2a topline results for tegoprubart in ALS patients
Tegoprubart met primary safety and tolerability endpoints; no drug-related serious adverse events observed.
Eledon Pharma Q1 net loss $9.9M; ALS topline data expected June 2022
Net loss $9.9M ($0.69/diluted share) vs $8.5M ($0.57) in Q1 2021.
Eledon Pharma reports FY2021 net loss of $34.5M; cash $84.8M into 2024
Net loss for Q4 2021 was $8.8M ($0.59/share); FY2021 net loss $34.5M ($2.33/share).
Eledon exchanges 550K common for Series X1 preferred; convertible at 55.56 per share
Exchanged 550,000 common shares for 9,899.99 Series X1 preferred shares with BVF entities.
Eledon Q3 net loss of $9.8M ($0.66/sh); pipeline progress in ALS, IgAN, transplant
Net loss of $9.8M for Q3 2021 vs $6.1M; R&D expenses surged to $7.7M from $0.6M.
Eledon posts Q2 net loss $7.4M; advances AT-1501 into kidney transplant, IgAN trials
Net loss $7.4M ($0.50/share) vs $2.6M loss in Q2 2020; R&D spend rose to $4.2M from $0.8M.
Jon Kuwahara resigned as SVP, Finance & Administration and Principal Accounting Officer effective July 31, 2021.
Eledon appoints Jan Hillson, M.D. as independent director; grants option for 40,000 shares
Jan Hillson, M.D. appointed to Eledon board effective July 1, 2021; qualifies as independent under Nasdaq rules.
On September 29, 2023, Allan Douglas Kirk, MD, PhD, FACS, was appointed to the board of directors (the “Board”) of Eledon Pharmaceuticals, Inc., (“Eledon”), effective October 2, 2023.
On September 11, 2023, James Robinson was appointed to the board of directors (the “Board”) of Eledon Pharmaceuticals, Inc., (“Eledon”), effective October 1, 2023.
On April 26, 2023, Gary A. Lyons notified the Company that he is retiring from the Board of Directors of the Company at the end of his term and will not be standing for election at the Company’s 2023 annual meeting of stockholders.
the Company’s Board of Directors appointed Paul Little as the Company’s Principal Accounting Officer, effective as of July 31, 2021.
Effective July 31, 2021, Jon Kuwahara resigned as the Senior Vice President, Finance & Administration and Principal Accounting Officer of Eledon Pharmaceuticals, Inc. (the “Company”).
On July 1, 2021, Jan Hillson, M.D. was appointed to the board of directors (the “Board”) of Eledon Pharmaceuticals, Inc., (“Eledon”).
Max materiality 0.90 · Median 0.65 · Most common event other_material